Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US02043Q1076
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000BFGNJ5
ALNY
Alnylam Pharmaceuticals Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Alnylam Pharmaceuticals Inc
ISIN
US02043Q1076
TICKER
ALNY
MIC
XNAS
REUTERS
ALNY.OQ
BLOOMBERG
ALNY US
Mon, 24.08.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. The...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 22.08.2026       Alnylam Pharmaceuticals
US02043Q1076

RADNOR, Pa., Aug. 22, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc....
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.08.2026       Alnylam Pharmaceuticals
US02043Q1076

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT TH...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sun, 16.08.2026       Alnylam Pharmaceuticals
US02043Q1076

RADNOR, Pa., Aug. 16, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc....
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 15.08.2026       Alnylam Pharmaceuticals
US02043Q1076

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant fin...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Alnylam Pharmaceuticals
US02043Q1076

LOS ANGELES, Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of the securities laws. INVESTIGATION DETAILS: The investigat...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Alnylam Pharmaceuticals
US02043Q1076

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued fa...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Alnylam Pharmaceuticals
US02043Q1076

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MON...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Alnylam Pharmaceuticals
US02043Q1076

Law Offices of Howard G. Smith announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ALNYLAM PHARMACEUTICALS, INC. (ALNY), CONTACT THE LAW OFFICES OF HOWARD G. SM...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Alnylam Pharmaceuticals
US02043Q1076

The Law Offices of Frank R. Cruz announces an investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALNYLAM PHARMACEUTICALS, INC. (ALNY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 30.07.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2026, and reviewed recent business highlights. “During the first half of 2026, we continued to meaningfully advance our business, generating over $1 billion in quarterly prod...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.07.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2026 results as well...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.07.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer’s Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurolog...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Fri, 12.06.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 10th series of “RNAi Roundtable” webinars over the coming months. The series will offer presentations from Alnylam scientists and physicians who will review recent progress in a selection of the Company’s pipeline programs...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.06.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cash an...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.05.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, “Accepting...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.05.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.05.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 04.05.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2026, and reviewed recent business highlights. “2026 is off to a strong start for Alnylam with the end of the first quarter marking one year since the U.S. launch of AMVUTTRA...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 16.04.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2026 results as well...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American College of Cardiology’s Annual Scientific Session and Expo (ACC.26), reinforcing the potential of RNAi to deliver fundamentally differentiated, effect...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.03.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Through complementary initiatives with...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 10.03.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company’s website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event....
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 9:10 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s website...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.02.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2025 and reviewed recent business highlights. “2025 was a year of key accomplishments for Alnylam, highlighted by the landmark approval of AMVUTTRA for ATTR...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 29.01.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February 12, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sun, 11.01.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with dis...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:00 am PT (12:00 pm ET) at The Westin St. Francis in San Francisco. During the...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.12.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-li...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.12.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% Convertible Senior Notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggre...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.12.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam’s Board, stepped down effective December...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 08.11.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneu...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida Jefferies Global Healthcare Conference o...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.10.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights. “Alnylam’s impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.10.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2025 results a...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.10.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), a global Phase 3 cardiovascular outcomes trial (CVOT) designed to evaluate the potential of zilebesiran, an investigational biannual subcuta...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.09.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the pricing of its previously announced private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.09.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the S...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sun, 31.08.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 30.08.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program,...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.07.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. “Our results during the second quarter highlight Alnylam’s unique ability to quickly deliver and enable commercial access to inn...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.07.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.07.2025       Alnylam Pharmaceuticals
US02043Q1076

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via su...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.06.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. Building on the launch of AMVUTTRA® in transthyretin amyloidosis with car...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.06.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therape...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.05.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET. A live audio webcast of the presentation will be available on the Investors section of the Compan...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Tue, 20.05.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This y...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Sat, 17.05.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Soc...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Alnylam Pharmaceuticals
US02043Q1076

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade,...
Read more
Alnylam Pharmaceuticals
Technical Analysis Termsheets Terminal
Permalink